系統性幼年特發性關節炎市場－全球產業規模、佔有率、趨勢、機會和預測，按治療類型、給藥途徑、配銷通路、地區和競爭細分，2020 年至 2030 年

2024 年全球系統性幼年特發性關節炎 (sJIA) 市值為 18.3 億美元，預計到 2030 年將達到 24 億美元，預測期內年複合成長率(CAGR) 為 4.61%。該市場涵蓋系統性幼年特發性關節炎（一種罕見且嚴重的幼年特發性關節炎亞型）的發展、診斷、治療和管理。

sJIA 是一種複雜的自體免疫疾病，主要影響兒童，其特徵是全身性發炎、高燒、皮疹和關節疼痛，並可能引發器官損傷等併發症。市場涵蓋廣泛的治療解決方案，包括旨在改善患者治療效果和生活品質的藥品、生物製劑、醫療器材和支持性護理策略。

關鍵市場促進因素

生物療法的進展

主要市場挑戰

治療費用高昂

主要市場趨勢

個人化醫療

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球系統性幼年特發性關節炎市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依治療類型（藥物治療{抗發炎藥物（NSAIDS）、腫瘤壞死因子（TNF）阻斷劑、肌肉鬆弛劑、免疫抑制劑、改善病情的抗風濕藥物、其他}、生物製劑、其他）
  • 依給藥途徑（口服、注射、其他）
  • 按配銷通路（醫院藥房、零售藥房、網路藥房）
  • 按公司分類（2024）
  • 按地區
• 市場地圖

第6章：北美系統性幼年特發性關節炎市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 墨西哥
  • 加拿大

第7章：歐洲系統性幼年特發性關節炎市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 法國
  • 德國
  • 英國
  • 義大利
  • 西班牙

第 8 章：亞太系統性幼年特發性關節炎市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 韓國
  • 日本
  • 澳洲

第9章：南美洲系統性幼年特發性關節炎市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲系統性幼年特發性關節炎市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 最新動態
• 產品發布
• 併購

第 13 章： 大環境分析

第 14 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 15 章：競爭格局

• Novartis AG
• Hoffmann-La Roche Ltd
• Takeda Pharmaceutical Company Limited
• Bristol - Myers Squibb Company
• Cadila Healthcare Ltd.
• Genetech, Inc.
• LATAM Pharma
• Alteogen Inc.
• Johnson & Johnson
• Momenta Pharmaceuticals, Inc.

第 16 章：策略建議

第17章調查會社について,免責事項

Global Systemic Juvenile Idiopathic Arthritis (sJIA) Market was valued at USD 1.83 billion in 2024 and is projected to reach USD 2.40 billion by 2030, registering a compound annual growth rate (CAGR) of 4.61% during the forecast period. This market encompasses the development, diagnosis, treatment, and management of systemic JIA-a rare and severe subtype of juvenile idiopathic arthritis.

sJIA is a complex autoimmune condition primarily affecting children and is marked by systemic inflammation, high fevers, skin rashes, and joint pain, with potential complications including organ damage. The market spans a broad spectrum of therapeutic solutions, including pharmaceuticals, biologics, medical devices, and supportive care strategies aimed at improving patient outcomes and quality of life.

Key Market Drivers

Advancements in Biologic Therapies

The increasing global burden of chronic autoimmune diseases is a key contributor to the growth of the sJIA market. Although systemic JIA is a rare pediatric autoimmune condition, it benefits from broader developments in autoimmune disease research and treatment.

According to a study published in Frontiers in Immunology (PMC9918670), the incidence of autoimmune diseases has increased by 19.1%, with a 12.5% rise in prevalence annually. This trend has intensified global focus and investment in autoimmune research, accelerating the development of new treatment approaches for conditions such as sJIA.

Research into more common autoimmune disorders-such as lupus and rheumatoid arthritis-has uncovered shared immunological pathways that are informing the development of novel and repurposed therapies for sJIA. Healthcare systems are also shifting toward integrated, patient-centered chronic disease management models, prioritizing early diagnosis, personalized care plans, and coordinated treatment approaches.

In the United States, the CDC reports that approximately 220,000 children and adolescents live with arthritis-related conditions, including sJIA (MMWR Morb Mortal Wkly Rep 2023;72:793-798). This growing pediatric population is prompting improved screening and referral systems, which in turn are enhancing early detection and treatment outcomes.

Pharmaceutical companies are responding to this demand by investing heavily in biologics and other targeted therapies specifically designed for pediatric autoimmune conditions. These innovations are reshaping the treatment landscape, improving clinical outcomes, and enhancing quality of life for affected children.

Key Market Challenges

High Treatment Costs

One of the most significant barriers to effective care in the Global sJIA Market is the high cost associated with treatment. Managing sJIA typically involves a comprehensive, multidisciplinary approach, including medications to control systemic inflammation and prevent long-term complications.

A major cost driver is the use of biologic therapies, particularly IL-1 and IL-6 inhibitors, which have proven highly effective in treating sJIA. However, these advanced biologics are among the most expensive drugs on the market and often require long-term administration, leading to a substantial financial burden for patients and healthcare systems.

Beyond the cost of medications, managing sJIA often involves routine monitoring, imaging studies, physical therapy, and consultations with multiple specialists. These ancillary costs can further strain healthcare budgets and impose significant financial challenges on families.

Key Market Trends

Personalized Medicine

Personalized medicine is increasingly shaping the future of the sJIA market by offering more tailored and effective treatment approaches based on an individual's genetic, molecular, and clinical profile. This patient-specific strategy is helping optimize therapeutic outcomes while reducing risks associated with traditional trial-and-error treatment methods.

In sJIA care, the use of advanced molecular and genetic profiling tools enables clinicians to better understand disease mechanisms and identify actionable molecular targets. This facilitates the development of highly specialized treatment plans that address the unique disease pathways of each patient.

A key advantage of personalized medicine is its predictive capability-allowing healthcare providers to determine which patients are most likely to respond favorably to specific biologics or immunosuppressive therapies. This not only enhances treatment efficacy but also reduces exposure to ineffective medications and associated side effects.

Furthermore, personalized dosing strategies ensure that patients receive the most appropriate therapeutic regimen, enhancing treatment safety and improving overall patient outcomes. As this approach becomes more widely adopted, it is expected to significantly advance the management of sJIA and reinforce the market's growth trajectory.

Key Market Players

• Novartis AG
• Hoffmann-La Roche Ltd
• Takeda Pharmaceutical Company Limited
• Bristol - Myers Squibb Company
• Cadila Healthcare Ltd.
• Genetech, Inc.
• LATAM Pharma
• Alteogen Inc.
• Johnson & Johnson
• Momenta Pharmaceuticals, Inc

Report Scope:

In this report, the Global Systemic Juvenile Idiopathic Arthritis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Systemic Juvenile Idiopathic Arthritis Market, By Treatment Type:

• Drug Treatment
• Biologics
• Other

Global Systemic Juvenile Idiopathic Arthritis Market, By Route of Administration:

• Oral
• Injectables
• Other

Global Systemic Juvenile Idiopathic Arthritis Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Systemic Juvenile Idiopathic Arthritis Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Systemic Juvenile Idiopathic Arthritis Market.

Available Customizations:

Global Systemic Juvenile Idiopathic Arthritis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Systemic Juvenile Idiopathic Arthritis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment Type (Drug Treatment {Anti-inflammatories (NSAIDS), Tumor Necrosis Factor (TNF) Blockers, Muscle Relaxants, Immune Suppressants Drugs, Disease Modifying Antirheumatic Drugs, Others}, Biologics, Other)
  • 5.2.2. By Route of Administration (Oral, Injectables, Other)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Systemic Juvenile Idiopathic Arthritis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment Type
  • 6.2.2. By Route of Administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment Type
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Mexico Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment Type
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Canada Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment Type
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By Distribution Channel

7. Europe Systemic Juvenile Idiopathic Arthritis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment Type
  • 7.2.2. By Route of Administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment Type
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Germany Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment Type
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment Type
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment Type
      • 7.3.4.2.2. By Route of Administration
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment Type
      • 7.3.5.2.2. By Route of Administration
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Systemic Juvenile Idiopathic Arthritis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment Type
  • 8.2.2. By Route of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment Type
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment Type
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. South Korea Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment Type
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. Japan Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment Type
      • 8.3.4.2.2. By Route of Administration
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment Type
      • 8.3.5.2.2. By Route of Administration
      • 8.3.5.2.3. By Distribution Channel

9. South America Systemic Juvenile Idiopathic Arthritis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment Type
  • 9.2.2. By Route of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment Type
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment Type
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment Type
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Systemic Juvenile Idiopathic Arthritis Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment Type
  • 10.2.2. By Route of Administration
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment Type
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment Type
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment Type
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Novartis AG
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (In case of listed companies)
  • 15.1.5. Recent Developments
  • 15.1.6. SWOT Analysis
• 15.2. Hoffmann-La Roche Ltd
• 15.3. Takeda Pharmaceutical Company Limited
• 15.4. Bristol - Myers Squibb Company
• 15.5. Cadila Healthcare Ltd.
• 15.6. Genetech, Inc.
• 15.7. LATAM Pharma
• 15.8. Alteogen Inc.
• 15.9. Johnson & Johnson
• 15.10. Momenta Pharmaceuticals, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer